CSPC Pharmaceutical Group (01093.HK): Phase III Clinical Trial of SYS6010 Combined with Enlimomab as Adjuvant Therapy for NSCLC Officially Launched
NewTimeSpace News: On June 30, 2026, CSPC Pharmaceutical Group (01093.HK) released a voluntary announcement, stating that the Group has officially launched the Phase III clinical study SYS6010-015 in China. The trial is designed to assess the safety and efficacy of SYS6010 combined with enlimomab as adjuvant treatment for patients with resected stage II–IIIB driver-gene-negative non-small cell lung cancer who failed to achieve major pathological response (MPR). Enrolment of the first trial participant is targeted for July 2026.
As stated in the announcement, SYS6010 is an independently developed EGFR-targeted antibody-drug conjugate (ADC) by CSPC Pharmaceutical Group. It is constructed by conjugating a humanized anti-EGFR monoclonal antibody with a topoisomerase I inhibitor payload via a cleavable linker. Enlimomab Injection is a recombinant fully human anti-PD-1 monoclonal antibody.
NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.
- CSPC Pharmaceutical Group (01093.HK): Second Marketing Application for Idaglutide Alpha Injection Accepted by NMPA
- CSPC Pharmaceutical Group (01093.HK): New Drug Application for Valsartan Levoamlodipine Maleate Tablets Accepted
- CSPC Pharmaceutical Group (01093.HK): Albumin-bound Paclitaxel for Injection (II) Approved for Marketing
- CSPC PHARMA(01093.HK): Phase III Study of Anistolimab Combined with HB1801 for HER2-positive Advanced Breast Cancer Meets Primary Endpoint
